Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics

Viking Therapeutics, Inc. (VKTX): $69.41

1.46 (-2.06%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

VKTX Price/Volume Stats

Current price $69.41 52-week high $99.41
Prev. close $70.87 52-week low $8.28
Day low $68.90 Volume 1,527,742
Day high $70.81 Avg. volume 6,020,928
50-day MA $60.31 Dividend yield N/A
200-day MA $26.17 Market Cap 7.65B

VKTX Stock Price Chart Interactive Chart >


Viking Therapeutics, Inc. (VKTX) Company Bio


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


VKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream


Loading social stream, please wait...

View Full VKTX Social Stream

Latest VKTX News From Around the Web

Below are the latest news stories about VIKING THERAPEUTICS INC that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?

Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.

Yahoo | December 12, 2023

Why Viking Therapeutics Was Crushing It This Week

A multibillion-dollar deal in the healthcare industry helped lift the stock of a company, Viking Therapeutics (NASDAQ: VKTX), not directly involved in the transaction. As a result, according to data compiled by S&P Global Market Intelligence, Viking's share price was up by a whopping 39% week to date as of Friday before market open. The week kicked off with global pharmaceutical company Roche (OTC: RHHBY) announcing it signed an agreement essentially to acquire clinical-stage biotech Carmot Therapeutics.

Yahoo | December 8, 2023

Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer — Here Are 2 Stocks to Take Advantage

A key to success in the stock market is a touch of foresight. Not quite precognition, but an ability to spot and put together clues and trends, to discern the ‘next big thing’ before it hits. This is true in every stock sector, but today we’ll focus on biotech. The biotech firms have famously high product lead times, paired with equally high overhead expenses; it’s a combination that would make them unlikely investments, except that when a drug is approved, it can turn into a blockbuster. Succes

Yahoo | December 3, 2023

Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company

Key Insights Significantly high institutional ownership implies Viking Therapeutics' stock price is sensitive to their...

Yahoo | November 28, 2023

Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The latest findings from the VOYAGE study were featured in a late breaki

Yahoo | November 13, 2023

Read More 'VKTX' Stories Here

VKTX Price Returns

1-mo -3.54%
3-mo 223.74%
6-mo 533.88%
1-year 272.77%
3-year 1,076.44%
5-year 642.35%
YTD 272.97%
2023 97.98%
2022 104.35%
2021 -18.29%
2020 -29.80%
2019 4.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!